Green Cross Biotherapeutics receives Health Canada approval for Phase 3 clinical trials of IVIG 10%

Ochang facility fractionation equipment 1Montreal, QC – Green Cross Biotherapeutics (GCBT), a Montréal-based biopharmaceutical company and subsidiary of Green Cross , reports that Health Canada has approved its application to proceed with a multi-centre Phase 3 clinical trial for its Immune Globulin Intravenous (Human) 10% GC5107 (IVIG 10%) product.

Please Login to view this Content. (Not a member? Join Today!)
Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.